Efficacy of Transcatheter Arterial Chemoembolization Combined with Tislelizumab in the Treatment of Primary Liver Cancer and Its Impact on Cancer-promoting and Cancer-suppressing Genes
ZHAO Yangguang
LI Ao
ZHANG Qian
YAN Shaohui
LI Jianmei
Abstract：Objective To investigate the efficacy of transcatheter arterial chemoembolization(TACE)combined with Tislelizumab in the treatment of primary liver cancer and its impact on cancer-promoting and cancer-suppressing genes.Methods Seventy-five patients with primary liver cancer admitted from October 2018 to March 2023 were selected,and then assigned to the control group(n=37)and the observation group(n=38)using the random number table method.Both groups were treated with Lenvatinib.On this basis,the control group received TACE,while the observation group received TACE combined with Tislelizumab.The efficacy,adverse reactions,and short-term survival rate,as well as the changes in tumor markers,angiogenesis-related factors,immune function indicators,and the expression of cancer-promoting and cancer-suppressing genes proteins before and after treatment,were compared between the two groups.Results The objective re-sponse rate and disease control rate in the observation group were higher than those in the control group(P＜0.05).After treatment,the levels of serum carcinoembryonic antigen,carbohydrate antigen 19-9,cytokeratin 19,alpha-fetoprotein,acidic fibroblast growth factor,vascular endothelial growth factor,basic fibroblast growth factor,and matrix metalloproteinase-9 in the observation group were lower than those in the control group(P＜0.05).After treatment,the levels of peripheral blood CD3+,CD4+/CD8+,and CD4+in the observation group were higher than those in the control group.The expression lev-els of peripheral blood monocyte cysteine aspartate-specific protease-3 and phosphatidylinositol 3-kinase proteins were higher in the observation group than in the control group,while the expression levels of B lymphocyte tumor-2 and extracellular signal-regulated kinase proteins were lower in the observation group than in the control group(P＜0.05).There were no significant differences in the incidence of adverse reactions and post-treatment survival rates between the two groups(P＞0.05).Conclusion In the treatment of primary liver cancer,TACE combined with Tislelizumab can improve the therapeutic effect,inhibit neovascularization,and promote immune function recovery,showing a certain degree of safety.Its mechanism may be related to regulating the expression of cancer-promoting and cancer-suppressing gene,but it does not significantly improve sur-vival rate.
Keywords：Primary liver cancerTranscatheter arterial chemoembolizationTislelizumabTumor markerAngio-genesisOncogeneAntioncogeneSurvival rate
Publication Date：2025-05-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 38-44 )